---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-098505"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:37:59.036614+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Journey Medical licenses Qbrexza to Maruho for Asia; $19M upfront payment

## Summary
- Journey receives $19M non-refundable upfront payment from Maruho within 10 days of signing.
- Amendment to Japan license removes certain royalties and a $10M milestone but retains up to $45M in milestone payments.
- Exclusive license covers 13 Asian markets including South Korea, Taiwan, Hong Kong, and Southeast Asian nations.
- Maruho assumes Journey’s payment obligations to Dermira (Eli Lilly) for Territory sales.

## SEC filing metadata
- accession: 0001104659-23-098505
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465923098505/0001104659-23-098505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465923098505/tm2325553d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-098505
- JSON: https://secwatch.observer/filing/0001104659-23-098505.json
- Plain text: https://secwatch.observer/filing/0001104659-23-098505.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.